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Abstract
Background: Correct staging and grading of patients with clear cell renal cell carcinoma (cRCC) is of clinical relevance
for the prediction of operability and for individualized patient management. As partial or radial resection with
postoperative tumor grading currently remain the methods of choice for the classification of cRCC, non-
invasive preoperative alternatives to differentiate lower grade from higher grade cRCC would be beneficial.
Methods: This institutional-review-board approved cross-sectional study included twenty-seven patients (8 women,
mean age ± SD, 61.3 ± 14.2) with histopathologically confirmed cRCC, graded according to the International Society of
Urological Pathology (ISUP). A native, balanced steady-state free precession T2 mapping sequence (TrueFISP) was
performed at 1.5 T. Quantitative T2 values were measured with circular 2D ROIs in the solid tumor portion
and also in the normal renal parenchyma (cortex and medulla). To estimate the optimal cut-off T2 value for
identifying lower grade cRCC, a Receiver Operating Characteristic Curve (ROC) analysis was performed and
sensitivity and specificity were calculated. Students’ t-tests were used to evaluate the differences in mean values for
continuous variables, while intergroup differences were tested for significance with two-tailed Mann-Whitney-U tests.
Results: There were significant differences between the T2 values for lower grade (ISUP 1–2) and higher grade (ISUP
3–4) cRCC (p < 0.001), with higher T2 values for lower grade cRCC compared to higher grade cRCC. The sensitivity and
specificity for the differentiation of lower grade from higher grade tumors were 83.3% (95% CI: 0.59–0.96) and 88.9%
(95% CI: 0.52–1.00), respectively, using a threshold value of ≥110 ms. Intraobserver/interobserver agreement for T2
measurements was excellent/substantial.
Conclusions: Native T2 mapping based on a balanced steady-state free precession MR sequence might support an
image-based distinction between lower and higher grade cRCC in a two-tier-system and could be a helpful addition to
multiparametric imaging.
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Background
Globally, renal cell carcinomas (RCC) have significant
impact with approximately 65,000 new cases in the
United States and 84,000 cases in the European Union
each year [1, 2], with clear cell renal cell carcinomas
(cRCC) being the most common subtype [3, 4]. Given
that lower grade cRCC carry a significantly better prog-
nosis than higher grade cRCC, it would be desirable to
individualize treatment options, which could entail a
radical approach for higher grade cRCC and a more con-
servative management such as active surveillance for
lower grade cRCC [5]. Currently, partial or radial resec-
tion with postoperative tumor grading remains the
method of choice for the classification of cRCC, because
image-based biopsies or fine needle aspiration remain
controversial due to their invasiveness, sampling errors,
and risk of needle tract seeding [6]. Therefore, non-
invasive preoperative alternatives to differentiate lower
grade from higher grade cRCC would be beneficial [6].
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Magnetic resonance imaging (MRI) is a non-invasive
imaging modality, not relying on ionizing radiation. T2
weighted MRI sequences allow for visualization of in-
flammation and edema [7]. While conventional MRI
only enables a qualitative image interpretation based on
signal intensity analysis with arbitrary units, T2 mapping
with voxel-wise evaluation of proton spin-spin relaxation
times allows for a non-invasive visualization and quanti-
fication of tissue composition [8]. As quantitative T2
values reflect tissue composition and, in particular, free
water content, T2 mapping is sensitive to tissue hydra-
tion or edema without the need for contrast agents and
thus shows the potential to become a ‘non-invasive bi-
opsy’ [9, 10].
While initially developed in the context of cardiac im-
aging, e.g. for quantification of myocardial edema as an
early predictor of myocardial injury [7], T2-weighted para-
metric mapping techniques are increasingly applied in
other organs, such as the liver or kidney, providing a
pixel-by-pixel map of various T2 relaxation times [11–13].
In the context of brain tumors, it was previously sug-
gested that tumors with higher cellularity showed a cor-
responding reduction in the extracellular fluid space
[14]. While lower grade cRCC are associated with small
nucleoli and low nuclear-to-cytoplasmic ratios, higher
grade cRCC are characterized by nuclear polymorphism,
higher cellularity and nuclear-to-cytoplasmic ratios [15],
whereby it can be assumed that the extracellular fluid is
subsequently decreased.
We hypothesized, that quantitative T2 mapping could
be used to distinguish lower from higher grade cRCC by
visualization of differences in tissue composition, e.g.
extracellular liquid. This proof-of-concept study there-
fore investigates the feasibility of a T2 mapping approach




This cross-sectional study was approved by the local In-
stitutional Review board with written consent obtained
from all participants prior to examinations. Between
January 2017 and October 2018, 42 consecutive patients
with suspected RCC, who agreed to participate, had no
previous ablations or contraindications to MRI, were
referred to our department for abdominal MRI. Out of
these, 27 patients with histologically validated cRCC
were included in the final analysis. The exclusions were
as follows: 3 patients with urothelial carcinomas, 2 pa-
tients with oncocytomas, 2 patients with atypical angio-
myolipomas, 2 patients without histologic examination
(missing data on the reference standard), 4 patients with
incorrect acquisition protocols and 2 patients with insuf-
ficient image quality due to motion artifacts.
Imaging protocol
Image acquisitions were performed using a 1.5 T clinical
MRI scanner (Avanto; Siemens Medical Solutions,
Erlangen, Germany) with dedicated 18-channel body and
spine matrix coils. Apart from a clinical routine image
protocol of the kidneys, the patients received a native,
balanced steady-state free precession T2 mapping se-
quence (T2-prepared single-shot TrueFISP) in coronal
plane, which was adjusted to the long axis of the kidney.
The routine imaging protocol of the kidney included a
coronal/sagittal T2 half Fourier single-shot turbo spin
echo sequence (HASTE), a native coronal 3D gradient
echo pulse T1-weighted (FLASH) sequence, a T1-
FLASH angiography (contrast agent: gadoterate meglu-
mine (Dotarem®, Guerbet, France), and a delayed fat sat-
urated 3D T1 VIBE (volumetric interpolated breath-hold
examination) sequence. Bolus tracking was used to de-
termine the first pass and 3D FLASH images were ob-
tained in the corticomedullary and nephrogenic phase.
The T2-preparation was an iterative Carr-Purcell
Malcom-Levitt (MLEV) sequence [16, 17]. T2 prepared-
TrueFISP images were acquired at intervals of 3 interbeat/
RR intervals with simulation of the electrocardiogram with
1 s per beat to allow for sufficient magnetization recovery
in between acquisitions. For each image, the acquisition
window was set in the same diastolic phase. The time
of acquisition for the TrueFISP sequence was 14 s per
slice acquisition, whereby T2 maps were acquired in
three slices. All T2 maps were acquired prior to ap-
plication of contrast agents. Please refer to Table 1
for detailed imaging parameters.
Table 1 Tabulated overview of MR imaging parameters
Sequence T2-HASTE True FISP* T1 3D-FLASH*
Scan plane Coronal Coronal Coronal
Voxel size (mm) 1.7 × 1.3 × 5.0 1.6 × 1.6 × 4.0 1.6 × 1.0 × 1.4
Number of slices 25 1 1
Slice thickness (mm) 5 4 1.40
TR/ TE (ms) 800/ 89 634.3/ 1.18 2.88/0.98
Averages 1 4 1
FoV (mm) 400 400 500
Flip angle (°) 170 70 25
Matrix 320 256 512
Bandwidth (Hz/Px) 422 930 440
Fat saturation None None Yes
Parameter map type – T2 map (2D) –
Number of T2 preps
(lengths in ms)
– 3 (0; 24; 55) –
Echo spacing (ms) – 2.8 –
Phase encoding direction R> > L R> > L R> > L
Descriptions: *FISP: Fast imaging with steady-state free frecession.
**FLASH: Fast low-angle shot
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T2 maps were automatically calculated on a pixel-by-
pixel basis, based on the assumption of mono-exponential
signal decay. They were displayed by a customized 12-bit
lookup table with a visible colour map, whereby the signal
intensity of each pixel reflected its absolute T2 value.
Imaging evaluation
PACS workstations (centricity radiology; GE Healthcare)
were used for image evaluation/analysis. An evaluation
of T2 mapping images was performed independently by
two radiologists, who were blinded to the histopatho-
logical findings, enabling the assessment of interobserver
agreement. One radiologist repeated the measurements
after 2 weeks and two further ROI measurements were
conducted after 3 months to enable a comprehensive
intraobserver assessment. In large tumors with necrosis
zones, circular 2D ROIs were placed within the most
homogeneous and bright appearing portion of solid
tumor area on the basis of visual assessment (in the
postcontrast sequences), also in conjunction with T2-
weighted images and were set in as large an area as pos-
sible. In small tumors without apparent necrosis zones,
a circular 2D ROI was drawn around the entire tumor
to avoid measurement inaccuracies (for illustration of
exemplary measurements refer to Additional file 1:
Figure S1). The respective ROIs were then copied to the
TrueFISP (T2 mapping) sequence, using a semi-
automatic co-registration tool. In case of breathing or
motion artefacts, an additional visual correction was ap-
plied. As T2 maps were acquired within a single breath-
hold, there was not motion between the different T2¬
weighted images. In all cases, it was taken care not to in-
clude the normal renal cortex, perinephric or sinus fat
within the measured ROIs. Regions of necrosis and cys-
tic degeneration were avoided and identified by lack of
enhancement on postcontrast images [18, 19]. In one pa-
tient, who did not receive postcontrast imaging due to
severe renal insufficiency, the initial 2D ROI was drawn
in the T2 HASTE image in the most solid and homoge-
neous appearing tumor portion and then copied to the
TrueFISP sequence. To measure the T2 values of renal
cortex and medulla, 2D ROIs were placed in a healthy
portion of the renal cortex and medulla, avoiding posi-
tioning on the boundary between cancerous and normal
parenchyma. In case of extensive tumor infiltration of
the kidney (which was the case in two patients), ROI
measurements of the renal cortex and medulla were per-
formed in the contralateral heathy kidney
ISUP grading
Resected cRCC specimens were examined by a patholo-
gist. They were then classified into four levels by the
International Society of Urological Pathology (ISUP)/
World Health Organization (WHO) [12]. Based on the
assessment of nuclear prominence, Grade 1 is defined by
inconspicuous/missing nuclei at × 400 magnification.
For grade 2, the nuclei are clearly visible at a magnifica-
tion of × 400 and for grade 3, the nuclei are visible at a
magnification of × 100. Finally, grade 4 tumors are
highly polymorphic, with rhomboid and/or sarcomatoid
differentiation [12].
Statistical analysis
All statistical analysis was performed with the statistical
software “R” (Version 3.2.2, R Development Core Team,
2015). Variables were averaged across measurements
and expressed as mean ± standard deviations in case of
normal distribution and with median and interquartile
range in absence of normal distribution. Students’ t-tests
were used to evaluate the differences in mean values for
continuous variables, while intergroup differences were
tested for significance using the two-tailed Mann-
Whitney-U test. Boxplots were created to show the dis-
tribution of the averaged quantitative T2 values among
the different grades. To estimate the optimal cut-off T2
value for identifying a lower grade cRCC, a Receiver
Operating Characteristic Curve (ROC) analysis was per-
formed with exploratory selection of the optimal cut-off
value. Sensitivity and specificity were calculated and
based on values averaged over the two observers.
Intraobserver and interobserver agreement were calcu-
lated using Bland Altman plots with limits of agreement
and corresponding confidence intervals, whereby for the
intraobserver agreement a graphical method for assess-
ment of more than two readings was used [20]. In
addition, the Coefficient of Variation (CoV) and the
intraclass coefficient (ICC) were calculated. For the ICC,
reliability was defined as excellent for values above 0.9,
as good for values between 0.75 and 0.90, as moderate
for 0.5–0.75 and as poor for values below 0.5 [21]. A
p-value < 0.05 was considered to indicate a significant
difference.
Results
The final study population consisted of 27 patients (19
men, 8 women, mean age, 61.3 ± 14.2; age range, 34–87
years) with histologically diagnosed cRCC. Figure 1 pro-
vides a study workflow and Table 2 gives an overview of
the study characteristics. 14 lesions were in the left kid-
ney and 13 lesions were located in the right kidney.
Histologic classification of patients revealed 8 ISUP
grade 1 lesions, 10 ISUP grade 2 lesions, 5 ISUP grade 3
lesions, and 4 ISUP grade 4 lesions. The maximum
cRCC diameter as determined in T2 HASE images,
using the longest tumor diameter in coronal sections,
was between 1.4 cm and 17 cm (median of 4, inter-
quartile range of 4.7). There was no difference in
tumor size between men and women (p = 0.21). The
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interval between MRI imaging and surgical removal
was 25.1 ± 20.7 days.
T2 mapping results for different tumor grades
The distribution of native T2 relaxation times across dif-
ferent tumor grades can be seen in Fig. 2. Exemplary T2
maps of cRCC patients with different ISUP grades are
shown in Fig. 3. T2 relaxation times were higher in
lower grade cRCC compared to higher grade cRCC
(132 ± 22 ms versus 97 ± 12 ms), with statistical ana-
lysis confirming a statistically significant difference
(p < 0.001). We also looked at the distribution of T2
values in the tumor area based on a whole-tumor-
approach, using density plots (refer to Additional file 2:
Figure S2 and Additional file 3: Figure S3.
Average T2 values were 134 ms ± 20 ms for ISUP
grade 1, 128 ms ± 21 ms for ISUP grade 2, 108 ms ±
19 ms for ISUP grade 3 and 96 ms ± 6 ms for ISUP
grade 4 tumors. For the normal renal cortex and me-
dulla, the average T2 values were 92 ± 16 and 85 ± 16,
respectively. There was no significant correlation
between values for renal medulla, cortex and the
glomerular filtration rate (r = 0.21, p = 0.89).
Diagnostic performance of T2 mapping
A ROC analysis was performed to determine the optimal
T2 cut-off-value for the distinction of lower grade from
higher grade cRCC. A cut-off-value of 110 ms could be
identified to detect lower grade cRCC with a sensitivity
of 83.3% (95% CI: 0.59–0.96) and a specificity of 88.9%
(95% CI: 0.52–1.00) (refer to Table 3 for confusion
matrix). However, four cases were wrongly diagnosed
based on T2 mapping: Three lower grade cRCC were in-
stead classified as higher grade cRCC based on their T2
values. Therefore, based on MRI, the severity of the case
was overestimated. And one higher grade cRCC was
wrongly classified as lower grade tumor. In this case,
MRI underestimated the severity of the case.
Intraobserver and interobserver agreement
Regarding intraobserver assessment, the confidence in-
tervals with a line of zero difference were 0 (95% CI: −
6.92 – 6.92) for cRCC with a Coefficient of Variation
(CoV) of 0.03, 0 (95% CI: − 6.74 – 6.74) for the renal
cortex with a CoV of 0.03 and 0 (95% CI: − 7.18 – 7.18)
for the medullary pyramids with a Coefficient of Vari-
ation (CoV of 0.03 (refer to Fig. 4). For interobserver as-
sessment, the mean differences between two observers
Fig. 1 Study workflow. Diagram illustrating the workflow of study participants and showing the reasons for exclusion as well as the final study
population, meeting the eligibility criteria
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were 1.81 (95% CI: − 10.24 – 13.87) for cRCC, − 2.5
(95% CI: − 14.34 – 9.34) for the renal cortex and − 0.59
(95% CI: − 13.17 – 11.98) for the medullary pyramids
(refer to Fig. 5). Corresponding to this, there was an ex-
cellent interobserver agreement for the cRCC T2 values
(ICC 0.97, 95% CI 0.94–0.99), the medullary T2 values
(ICC 0.92, 95% CI 0.85–0.96), and the cortex T2 values
(ICC 0.94, 95% CI 0.88–0.97).
Discussion
In this cross-sectional study, a quantitative T2 mapping
technique (TrueFISP) was used for the differentiation of
lower and higher grade cRCC. Lower grade cRCC (ISUP
grades 1, 2) showed significantly higher T2 values com-
pared to higher grade cRCC (ISUP grades 3, 4), support-
ing the potential of T2 mapping as a noninvasive marker
of cRCC grade.
While conventional, qualitative T2 weighted imaging is
subject to various limitations, such as the use of arbitrary
signal intensity scales for T2 values with subsequent test-
retest and interobserver variability, T2 mapping offers the
potential for a standardized, reproducible assessment of tis-
sue composition and water contents, e.g. facilitating the
diagnosis of interstitial edema and extracellular space ex-
pansion [22, 23]. It is based on the acquisition of multiple
T2-weighted images at different echo times (TE), with the
signal of the various TEs being fitted to an exponential sig-
nal decay model, generating an estimate of quantitative T2
values [24]. Direct quantification of the T2 signal provides a
benefit over T2-weighted imaging, minimizing dependency
on user-defined parameters and subjective interpretation.
Besides, differences between tissues might be detected
more easily [7]. In the context of cardiac imaging, T2
mapping offers advantages over conventional T2
weighted imaging, for example in the detection of
global myocardium changes in myocarditis or cardiac
allograft rejection [25, 26]. For oncological imaging,
T2 mapping was previously used for a range of differ-
ent malignancies, such as colorectal carcinoma, breast
and ovarian cancer, prostate carcinoma, glioblastoma
and brain metastases [27–32]. Only a handful of prior
studies focused on renal T2 mapping, e.g. showing
the potential to evaluate the renal parenchyma after
kidney transplantation and to improve the diagnosis/
progression of polycystic kidney disease [11, 33]. Medul-
lary T2 relaxation times were observed to be consistently
longer compared to cortical T2 relaxation times, which is
in accordance with the results of the present study [13].
To our knowledge, T2 mapping has so far not been
examined in the context of cRCC.
Non-invasive cRCC grading would not only improve
preoperative planning options, but also aid in prognosis
assessment and prior patient information, for example by
informing patients about the best individual therapy op-
tions. Furthermore, it may reduce the need for kidney
mass biopsies. In addition, it might prevent cases of up-
staging after partial nephrectomy in larger tumors, help
identify patients who might be eligible for immunother-
apy, and, finally, facilitate the selection of patients suitable
for less invasive therapies [27], including minimally inva-
sive procedures such as ablation, cryotherapy or even ac-
tive surveillance. In addition to image-based grading of
cRCC, image-based identification of different renal tumor
subtypes such as urothelial carcinomas, oncocytomas,
chromophobic RCC or lipid-poor angiomyolipomas would
also be highly beneficial, because it could reduce the num-
ber of unnecessary surgical resections (9, 39). In the
present study, however, the number of subtypes other
than cRCC was too small to allow a valid evaluation
(3 urothelial carcinomas, 2 oncocytomas, 2 atypical angio-
myolipomas). Further studies are warranted to better
assess the clinical feasibility of T2 mapping for the nonin-
vasive assessment of cRCC, focusing on the ability to
predict both tumor grade and subtype.
Regarding histology, cRCC consists of cells with clear
cytoplasm and necrosis with often occurring cystic de-
generation or hemorrhage [34]. Lower grade cRCC are
predominantly characterized by cystic changes, which
could serve as an explanation for the observed prolonged
relaxation times. Necrosis, on the other hand, is particu-
larly common in higher grade cRCC [6]. It does not only
occur as macroscopic necrosis, but also as micronecrosis
Table 2 Characteristics of the Study Population
Number of patients with cRCC
(men, percentage of total (%))
27 (19, 70.4)
Mean age of patients with cRCC ± SDa 61.3 ± 14.2
Median diameters for cRCC (IQRb)
ISUP grade 1 (IQR) 3.5 (1.13)
ISUP grade 2 (IQR) 3.95 (3.3)
ISUP grade 3 (IQR) 15.5 (3.8)
ISUP grade 4 (IQR) 5.6 (2.7)
Partial nephrectomy (number, %) 15, 55.6
Radical nephrectomy (number, %) 10, 37.0
Biopsy (number, %) 2, 7.4
Imaging Characteristics.
Average normal renal parenchyma T2 values (ms) ± SD
Renal cortex 85 ± 16
Renal medulla 92 ± 16
Average T2 values for cRCC (ms) ± SD (number, %)
ISUP grade 1 ± SD 134 ± 20 (8, 29.6)
ISUP grade 2 ± SD 128 ± 21 (10, 37.0)
ISUP grade 3 ± SD 108 ± 19 (5, 18.5)
ISUP grade 4 ± SD 96 ± 6 (4, 14.8)
aSD Standard deviation, bIQR Interquartile range
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below the spatial resolution of MRI [6, 35, 36]. In the
present study, false negative results (lower grade cRCC
with T2 values below 110ms) could thus have resulted
from including areas of (micro)necrosis within the ROI
analysis [37, 38]. Decreased T2 relaxation times in higher
grade tumors may be based on the presence of densely
packed proliferating cells, interstitial reticulin deposition
and/or irregular tumor vasculature [39, 40]. The false
positive result in our study could have resulted from the
inclusion of (micro)cystic components.
Although a considerable difference in the average T2
relaxation times between lower grade and higher grade
cRCC was observed in a two-tier-system, there was a
significant overlap between the subgroups (ISUP 1,2 and
ISUP 3,4) with no apparent difference. As a conse-
quence, based on our data, it was not possible to differ-
entiate between ISUP grade 1 and 2 or ISUP grade 3 and
4 tumors. However, the number of patients in the sub-
groups, especially regarding higher grade tumors, was
very small and future studies with larger case numbers
might help to assess the feasibility of T2 mapping in a
four-tier-grading system, potentially allowing for/leading
to T2 mapping value reference ranges with diagnostic
utility. On route towards renal T2 mapping as a
Fig. 2 Distribution of T2 across different tumor grades (ISUP grades). The upper left part of the Fig. a displays the T2 differences across four different
ISUP grades using boxplots. And the upper right part of the Fig. b shows the T2 differences across a two-tier-system (ISUP 1,2 against ISUP 3,4). Lower
grade cRCC show higher T2 values compared to higher grade cRCC. The lower left part of Fig. C1 illustrates the diagnostic performance of T2
mapping as a binary classifier in discriminating between ISUP grades 1–2 and 3–4. In this context, the T2 threshold is varied using a receiver
operation characteristic curve (ROC-curve). The corresponding Area under the Curve (AUC) is 0.93. The lower right part of the Fig. C2
displays the respective sensitivity and specificity values plotted against their corresponding threshold. The centerline in each box represents the
median, whereas the lower and upper limits of each box represent the 25th and 75th percentiles, respectively. Whiskers extend to the most
extreme observations within 25th and 75th percentiles ±1.5 x interquartile range. Observations outside these whiskers are shown as dots
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potential additional biomarker, it will, furthermore, be
necessary to validate T2 mapping against accepted refer-
ence measurements, such as nuclear medicine evalua-
tions as well as histological findings [13].
In the context of future clinical applications, the use of
T2 mapping might be a helpful addition to multipara-
metric imaging instead of being used exclusively. To this
end, a novel T2-mapping-derived parameter could be in-
tegrated into a multiparametric MR imaging model. In
the context of radiomics, it could also be included as a
quantitative imaging feature, be converted into minable
data and aid in the building of predictive models. It can
be expected, that multiparametric approaches will yield
superior diagnostic performance, when compared to sin-
gle imaging parameters alone. Therefore, in the future,
multiparametric approaches may enable reliable, nonin-
vasive grading of cRCC.
Regarding practicability, the T2 mapping approach
chosen in the present study would be easy to implement
in a clinical setting, as no complex mathematical model-
ling is required and the TrueFISP sequence is already
commercially available on some MR scanners. Further-
more, it enables the acquisition of T2 maps during MRI
scanning with a short scanning time. TrueFISP has been
Fig. 3 Exemplary T2 mapping images of lower and higher grade cRCC. 1a, coronal T2 HASTE image of a 77-year-old man with a low grade (ISUP
1) cRCC of the left kidney. 1b, postcontrast T1 FLASH image. 1c, corresponding TrueFISP image, showing a high T2 signal. 2a, T2 HASTE image of
a 57-year-old woman with a lower grade (ISUP 2) cRCC of the right kidney. 2b, postcontrast T1 FLASH image. 2c, corresponding TrueFISP image,
also showing a high T2 signal (2d). 3a, coronal T2 HASTE image of a 62-year-old man with a higher grade (ISUP 3) cRCC of the right kidney. 3b,
postcontrast T1 FLASH image. 3c, corresponding TrueFISP image, showing a low T2 signal. 4a, coronal T2 HASTE image of a 71-year-old man with
a high grade (ISUP 4) cRCC of the right kidney. 4b, postcontrast T1 FLASH image. 4c, corresponding TrueFISP image, showing a low T2 signal.
1c-m1, 2c-m1, 3c-m1 and 4c-m1 are magnifications of 1c, 2c, 3c and 4c
Table 3 Confusion matrix for the calculation of diagnostic accuracy
MR native T2 mapping
(index test)
Pathology (reference standard) Total
Confirmed lower grade cRCC Confirmed higher grade cRCC
Lower grade cRCC
(ISUP grades 1, 2)
15 1 16
Higher grade cRCC
(ISUP grade 3, 4)
3 8 11
Total 18 9 27
Adams et al. Cancer Imaging           (2019) 19:35 Page 7 of 11
previously shown to be a robust method for T2 mapping,
combining T2-magnetization preparation with steady-
state free precession imaging and being sufficiently fast to
be acquired in a single breathhold [41]. An advantage of
T2-prepared single-short TrueFISP is its high signal-to-
noise-ratio (SNR) and low sensitivity to breathing artifacts,
which can be especially helpful in the assessment of cRCC,
as kidney imaging is often limited by respiratory motion
artefacts because of the location in the upper abdomen
[7, 42]. Potential disadvantages of TrueFISP result from
Fig. 4 Intraobserver agreement of cortex, medullary and tumor T2 values. Bland-Altman plots, showing agreement between four different
readings for measurement of T2 values (a, tumor tissue; b, renal cortex; c, renal medulla). The upper and lower reference lines indicate
the upper and lower limits of agreement (95% confidence intervals). The confidence intervals for the mean and limits of agreement are
indicated by the dotted lines. CoV: Coefficient of variation
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the fact, that the number of acquired echoes is consider-
ably lower compared to other techniques such as Multi
Echo Spin Echo (MESE), providing only a limited number
of data points along the T2 decay curve and thus
potentially compromising accuracy and limiting its use to
a narrower range of T2 species [43].
Due to the relatively long T2 relaxation times of the
kidneys, ideally longer T2 preparation times with more
than three weightings are used. While a repetition
time of 1000ms allows for time-efficient acquisition
within a single breathhold, it does not ensure complete
signal recovery. Therefore, the T2 maps in the present
study are partly influenced by renal T1 signal and do not
correspond to a pure T2 signal. To overcome this limita-
tion in future studies, either the time of repetition can
be increased (with a subsequent increase in scan time)
or the flip angle can be reduced (with a decrease in
SNR). However, within the scope of the present proof,
we first aimed to investigate if a cardiac T2 mapping ap-
proach would be feasible for kidney imaging at all. An-
other limitation of this proof-of-concept study is, that it
was based on a single-center design, only measuring T2
values at one time point prior to the intervention/sur-
gery and including a small number of patients, especially
with regard to higher grade cRCC. The small number of
images was also an important limitation for assessment
of intraobserver and interobserver agreement. In
addition, the exclusion of other subtypes of renal masses
brings about the risk of potential selection bias. Also,
even though larger areas of necrosis were excluded,
smaller necrotic regions may have been included in the
ROI measurements and might have affected T2 mea-
surements. Furthermore, the T2 relaxation time of the
tumor was only measured in one representative cor-
onal plane, not in the whole tumor. Besides, no
automatic motion or alignment correction was applied
to correct for misregistrations between the different
sequences. Therefore, slight misalignments cannot be
completely excluded. Apart from that, even though
patients were advised not to thirst and to drink water
in the morning before the MRI, this was not explicitly
controlled prior to the examination and patients were
not instructed to drink a specific amount of water.
Therefore, patients may have exhibited certain fluctu-
ations in the hydration status, which could have af-
fected T2 measurements in the renal parenchyma and
potentially also in the tumor tissue. Finally, only one
scanner from one vendor was used, therefore the re-
sults may not be generalizable to other institutions.
Further investigations will be required to validate T2
mapping as a tool for cRCC assessment.
Conclusions
There was a significant difference in average T2 relaxation
times between lower grade and higher grade cRCC, with
lower grade cRCC showing significantly longer T2 relax-
ation times compared to higher grade cRCC. We therefore
believe, that this technique holds potential for the future
to noninvasively assess cRCC tumor grade in vivo and
could provide a helpful addition to multiparametric im-
aging. However, studies with larger patient cohorts and a
broader range of higher grade tumors are required to ex-
plore the utility of T2 mapping as a possible primary diag-
nostic MRI sequence for cRCC grading.
Additional files
Additional file 1: Figure S1. Visualization of circular 2D ROI placement
for smaller tumors without and larger tumors with apparent necrosis
Fig. 5 Interobserver agreement of cortex, medullary and tumor T2 values. Interobserver agreement of the cortex, medullary and tumour T2
values. Bland-Altman plots illustrate the interobserver variability for native cRCC, medullary and cortex T2 values. Specifically, the mean differences
were 1.95 (95% confidence interval (CI): − 8.61 – 12.52) for the cRCC tumor area with a CoV of 2.76, − 2.26 (95% CI: − 12.45– 7.94) for the renal
cortex with a CoV of − 2.3 and − 1.03 (95% CI: − 13.67 – 11.61) for the medullary pyramids with a CoV of − 6.26. The mean difference of the data
is illustrated by the central horizontal line. The upper and lower reference lines indicate the upper and lower limits of agreement. The confidence
intervals for the mean and limits of agreement are indicated by the dotted lines. CoV: Coefficient of variation
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zones for ISUP grades 1 to 4. ROIs were first placed in a corresponding
postcontrast image and then copied to the T2 map. (TIF 8355 kb)
Additional file 2: Figure S2. Segmentation of tumors (ISUP grades 1 to
4 from top to bottom, A-D) with creation of image masks (A2 through
D2). A3 through D3 show the calculated percentage densities of the
absolute T2 values. (TIF 2244 kb)
Additional file 3: Figure S3. The upper part of the figure illustrates the
percentage density of T2 values for whole-tumor measurements of the
four colour-coded ISUP grades (refer to the legend on the upper right
side). For each tumor, the T2 maps were segmented and image masks
were imported into the open access software ‘R’. The lower part of the
figure shows the colour-coded percentage density of T2 values for lower
grade tumors (combined ISUP grades 1 and 2) and higher grade tumors
(combined ISUP grades 3 and 4). (TIF 773 kb)
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